U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Status:
Investigational
Source:
INN:cinoquidox
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Cinoquidox is a quinoxaline derivative used in veterinary as an antibacterial agent and growth promotor. It was patented by Ciba-Geigy Corporation and was claimed to be effective in the case of diseases of the respiratory tract in poultry, and infections of the intestinal tract and of the urogenital system in domestic animals and productive livestock.
Status:
Investigational
Source:
NCT01246908: Phase 2 Interventional Completed Treatment Resistant Depression
(2010)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
USAN:VEDOTIN [USAN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Vedotin fragment (Monomethyl auristatin E, MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. MMAE is a potent radiosensitizer. MMAE radiosensitization can be localized to tumors by targeted activatable cell-penetrating peptides.
Status:
Investigational
Source:
NCT02964507: Phase 2 Interventional Active, not recruiting Neoplasms
(2017)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


GSK 525768A is inactive enantiomer of BET inhibitor, compound I-BET (GSK525762A). It was used as a negative controls in studies of I-BET.
Status:
Investigational
Source:
INN:hydromorphinol
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Hydromorphinol, an opioid, and is a derivative of morphine and possesses similar properties: sedation, analgesia, and respiratory depression. Hydromorphinol is under the control according to US Single Convention 1961.
Status:
Investigational
Source:
NCT02322021: Phase 2 Interventional Completed Alzheimer Disease
(2014)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT01053962: Phase 2 Interventional Completed Chronic Idiopathic Constipation
(2010)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Pirnabine is the synthetic dibenzopyran drug. It was developed as anti-glaucoma drug.
Status:
Investigational
Source:
INN:YOHIMBIC ACID [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Yohimbinic acid, also known as yohimbic acid is an indole alkaloid, which was isolated from dried roots of Rauwolfia serpentina. Yohimbinic acid is a potent inhibitor of a human DNA Topoisomerase I and can inhibit cancer cells growth.
Status:
Investigational
Source:
INN:DISERMOLIDE [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Disermolide (discodermolide) is the immunosuppressant and antineoplastic agent. The marine natural product discodermolide was first isolated in 1990 from the deep-water Caribbean sponge Discodermia dissoluta. It attacks cancer cells in a similar way to the successful cancer drug Taxol that has become the best-selling anticancer drug in history. Discodermolide is a microtubule-stabilizing agent with potential for the treatment of taxol-refractory malignancies. Discodermolide is a drug that functions as an immunosuppressant and induces G2/M phase cell-cycle arrest in lymphoid and non-lymphoid cells. The cytotoxicity of discodermolide cause cell-cycle arrest by mitosis and an important alteration at the level of microtubules. Discodermolide is a potent inducer of accelerated senescence. At present, Phase I trials with discodermolide has been discontinued as a consequence of unsafe efficacy and toxicity results.
Status:
Investigational
Source:
J Gynecol Obstet Biol Reprod (Paris). 1993;22(6):659-66.: Not Applicable Human clinical trial Completed N/A
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)